Recursion Pharmaceuticals reported mixed Q2 2026 results, with revenues dropping to $7.67 million and a net loss narrowing to $131.01 million. The company highlighted significant milestones in drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results